



EyeDura


Early-stage seed funded ophthalmic pharmaceutical company developing preservative-free **topical sustained release** eye drops that target both **anterior and posterior** eye conditions

May 2025



A **single drop** of the topical sustained release (TSR) formulation will deliver therapeutic levels of API for **seven days or longer**

The TSR vehicle is **compatible with most APIs** currently used in ophthalmic products, including both **small molecules and biologics**



API = Active pharmaceutical ingredient

INNOVATIVE SOLUTION: NOVEL MECHANISM OF ACTION




EyeDura

INNOVATIVE SOLUTION

A **single eye drop** is proven to deliver therapeutic medication levels for multiple days because:

- it is lipid-based
- has high viscosity
- integrates into the lipid phase of the tear film

**Product is Preservative Free
Vehicle Ingredients are GRAS***



During a blink, the aqueous layer is selectively removed while the lipid layer stays on.

The TSR drop resides on the lipid layer and therefore remains on the surface for extended periods and provides a stable depot

Imaging	Before EyeDura Drop	After EyeDura Drop
Lipid Layer (nm)	78	114
Aqueous Layer (nm)	3309	3421

*GRAS = generally recognized as safe

INSULIN TOPICAL EYE DROPS: COMPLETE HEALING OF EPITHELIAL DEFECTS




Probing Trial

- 1 A prospective non-randomized trial (Clinical Quesada, San Salvador)
- 2 Ten Patients with persistent epithelial defects (PEDs) that were **refractory** to conventional treatment were treated with TSR insulin
- 3 Patients' demographics, PED etiology, concomitant treatments, and comorbidities were reviewed

Case 1

Closure of the epithelial defect after 2 weeks, lower staining at border




DAY 1

DAY 22

Case 2

Closure of the epithelial defect after 3 weeks, lower staining at border



DAY 1

DAY 30




























After **2 drops/week** treatment with Insulin TSR drops, the **epithelial defects healed completely** in all ten patients by **Day 30**

TSR drops applied only 8 times over four weeks

The mechanism of insulin on the wound healing process is well documented (Jaworski et al., 2024)

STRONG GLOBAL PATENT PROTECTION: THROUGH 2044*



<div> USA</div> <div>11,234,926 </div> <div>11,497,710 </div> <div>12,280,141 </div> <div>18/650,914 </div>	<div> CHINA</div> <div>ZL201980044591.3 </div> <div>40046692 (HK) </div>	<div> AUSTRALIA</div> <div>2019263302 </div>	<div> SOUTH AFRICA</div> <div>2020/06573 </div>	<div> MEXICO</div> <div>401711 </div>	<div> CANADA</div> <div>3,097,927 </div>
	<div> BRAZIL</div> <div>BR1120200220876 </div>	<div> EUROPE</div> <div>19795860.6 </div>	<div> JAPAN</div> <div>2021510274 </div> <div>2024-108878 </div>	<div> KOREA</div> <div>10-2020-7034068 </div>	<div> SINGAPORE</div> <div>11202010742U </div>



Green = 8 issued



Purple = 8 published

*Additional pending applications in various countries

EYEDURA: PROVEN BOARD, STRONG LEADERSHIP TEAM & ADVISORS



Proven Board



Srini Venkatesh, PhD MBA

CEO

Board Member



William Link, PhD

Chairman



Kevin Waltz, OD MD

Co-Founder

Board Member



John Vukich MD

Co-Founder

Board Member

Strong Leadership Team



Jeevan Gore, JD



Mike Judy



Mark Vukich



**Jeffrey
Goldberg, MD
PhD**



**Adriana Di Polo
PhD**



**Theresa Heah,
MD MBA**



**Vernon Wong,
MD**



**Rob Humkey,
PhD MBA**

Expert Advisors